In this video, Stanley Riddell, MD, of Fred Hutchinson Cancer Research Center, Seattle, WA., discusses improving treatment outcomes with CAR T-cell therapy by identifying different targets such as CD22. Dr Riddell goes on to explain the latest research at Fred Hutchinson Cancer Research Center that looks at improving CAR design to improve outcomes. Recorded at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and European Hematology Association (EHA).